Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04451850 · ClinicalTrials.gov registry record
HRV as a Marker of Treatment Response in PAH Arterial Hypertension
A clinical trial, sponsored by University of Cincinnati.
- Completed
- Registry status
- 24
- Enrollment target
NCT04451850: Completed study, sponsored by University of Cincinnati.
NCT04451850 is a clinical trial that has completed, run by University of Cincinnati. The registered enrollment target is 24 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04451850 has completed, sponsored by University of Cincinnati.
- COMPLETED
- Registry status
- 24 participants
- Enrollment target
Study Summary
This is a prospective longitudinal cohort study to determine the value of HRV obtained using noninvasive actigraphy to quantify the response to pulmonary vasodilator therapy in newly diagnosed PAH patients
Primary Outcome
Change from baseline in Root Mean Squared Successive Differences (RMSSD) measure of Heart Rate variability in patients on targeted therapy
Interventions
- OTHER Noninvasive actigraphy monitor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2021-06-01 |
| Est. Completion | 2024-12-01 |
What the finished NCT04451850 record still lists
NCT04451850 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 24 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Noninvasive actigraphy monitor is the first listed.
NCT04451850 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04451850 about?
NCT04451850 is a clinical study titled "HRV as a Marker of Treatment Response in PAH Arterial Hypertension". This is a prospective longitudinal cohort study to determine the value of HRV obtained using noninvasive actigraphy to quantify the response to pulmonary vasodilator therapy in newly diagnosed PAH patients
What is the current status of trial NCT04451850?
This trial is currently completed. The enrollment target is 24 participants. The study started on 2021-06-01. Estimated completion is 2024-12-01.
What interventions are being tested in trial NCT04451850?
The interventions under investigation include: Noninvasive actigraphy monitor (OTHER).
Who is sponsoring clinical trial NCT04451850?
This trial is sponsored by University of Cincinnati, which has 245 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI